Manhattan Eye, Ear & Throat Hospital
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Manhattan Eye, Ear & Throat Hospital sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Manhattan Eye, Ear & Throat Hospital: 14 sponsored US clinical trials, none currently recruiting.
Manhattan Eye, Ear & Throat Hospital sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Central Serous Chorioretinopathy, with 1 trials.
Top-decile sponsor footprint
Manhattan Eye, Ear & Throat Hospital ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
NCT00211432
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
NCT00489840
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
NCT00470977
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
NCT00211458
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
NCT00211393
Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
NCT00211367
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
NCT00140803
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
NCT00211484
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
NCT00211445
Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).
NCT00211328
Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)
NCT00211315
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
NCT00211471
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
NCT00211419
Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
NCT00211406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
Therapeutic Areas
How the Manhattan Eye, Ear & Throat Hospital early-phase archive is shaped
14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).
Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Chronic Central Serous Chorioretinopathy (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Manhattan Eye, Ear & Throat Hospital: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Manhattan Eye, Ear & Throat Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Manhattan Eye, Ear & Throat Hospital page
14 registered trials is a research-attention snapshot, not an endorsement of Manhattan Eye, Ear & Throat Hospital or any single study.
- None of Manhattan Eye, Ear & Throat Hospital's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Central Serous Chorioretinopathy is the condition Manhattan Eye, Ear & Throat Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Central Serous Chorioretinopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Manhattan Eye, Ear & Throat Hospital pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.